Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria
Eos SENOLYTIX announced it will present at the 17th World Congress on Targeting Mitochondria in Berlin, October 21-23, with Founder and CEO Kevin Slawin delivering the industry keynote on its mitochondrial-targeted geropeptide platform. Lead candidate PTC-2105 remains preclinical, with IND-enabling studies underway ahead of first-in-human trials for sarcopenia and sarcopenic obesity. Eos reiterated that the Pulmatrix merger is expected to close in Q4 2026 following the October 16 Pulmatrix stockholder vote, with the combined company to trade under ticker MTXL.
Key figures
- Expected closing
- Q4 2026
- New ticker symbol
- MTXL
- Stockholder vote date
- October 16, 2026
- Xprize healthspan prize pool
- $101 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.